Valiant Laboratories Ltd's Q3FY25 Quarterly Results

Result Summary

• Valiant Laboratories Ltd reported a 48.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 13.0%.
• Its expenses for the quarter were up by 22.4% QoQ and down 25.6% YoY.
• The net profit decreased 149.6% QoQ and decreased 167.1% YoY.
• The earnings per share (EPS) of Valiant Laboratories Ltd stood at 0.5 during Q3FY25.

Financial Statments for Q3FY25

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Valiant Laboratories Ltd is a company involved in the [insert industry here] industry. The company focuses on producing and distributing [insert main products or services]. As of the latest available data, there are no specific recent major developments reported for Valiant Laboratories Ltd. Despite the lack of publicly available information on their recent activities, the company operates in a competitive market environment that can influence its financial performance. [If more detailed information on the company's activities or market presence were available, it would be included here.]

Revenue

In the third quarter of FY25, Valiant Laboratories Ltd reported a total income of ₹36.81 crores. This represents a quarter-over-quarter increase of 48.2% from ₹24.84 crores in the second quarter of FY25. Compared to the third quarter of FY24, where the total income was ₹42.29 crores, there is a year-over-year decrease of 13.0%. This indicates fluctuations in revenue generation over the periods in question, with a notable increase from Q2FY25 to Q3FY25, but a decline when compared to the same quarter in the previous fiscal year.

Profitability

Valiant Laboratories Ltd's profitability metrics show a substantial improvement in Q3FY25. The company recorded a profit before tax of ₹1.62 crores, a notable turnaround from the loss of ₹3.91 crores in Q2FY25 and an even larger loss of ₹5.04 crores in Q3FY24. This marks a quarter-over-quarter improvement of 141.4% and a year-over-year change of 132.1%. The profit after tax also saw a positive shift, with ₹2.35 crores in Q3FY25, compared to a loss of ₹4.74 crores in Q2FY25 and ₹3.50 crores in Q3FY24, reflecting a quarter-over-quarter improvement of 149.6% and a year-over-year change of 167.1%. Earnings per share have similarly improved from negative figures in previous periods to ₹0.50 in Q3FY25.

Operating Metrics

The total expenses for Valiant Laboratories Ltd in Q3FY25 were ₹35.19 crores, which is a 22.4% increase from ₹28.75 crores in Q2FY25. However, compared to Q3FY24's total expenses of ₹47.33 crores, there is a decrease of 25.6% year-over-year. This reduction in expenses from the previous year, coupled with the rise in total income this quarter, contributes to the company's improved profitability. The tax line item shows a reversal, with a credit of ₹0.73 crores in Q3FY25, compared to a tax expense of ₹0.83 crores in Q2FY25 and a credit of ₹1.54 crores in Q3FY24. This tax benefit positively impacts the net profitability of the company for the current quarter.